Prevalence of hepatitis C in a German prison for young men in relation to country of birth

Epidemiology and Infection

Volumn 135, Issue 2, 2007, Pages 274-280

  Meyer, M F ^a   Wedemeyer, Heiner ^a   Monazahian, M ^b   Dressman, J ^b   Manns, M P ^a   Lehmann, Marc ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Nieders chsisches Landesgesundheitsamt   (Germany)

^c Jugendanstalt Hameln ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; ETHNIC DIFFERENCE; FOLLOW UP; GENOTYPE; GERMANY; HEALTH EDUCATION; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; INFECTION PREVENTION; INFECTION RISK; LEBANON; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRISON; PRISONER; RISK FACTOR; STATISTICAL SIGNIFICANCE; USSR; VIREMIA;

ADOLESCENT; ADULT; CHI-SQUARE DISTRIBUTION; GENOTYPE; GERMANY; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; PRISONERS; RNA, VIRAL; USSR;

EID: 33847258756     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268806006820     Document Type: Article

References (28)

1. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002; 36: S93-S98.
2. WHO. Weekly Epidemiological Record, No. 49, 10 December 1999, World Health Organization.
3. Macalino GE, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. American Journal of Public Health 2004; 94: 1218-1223.
4. Baillargeon J, et al. Hepatitis C seroprevalence among newly incarcerated inmates in the Texas correctional system. Public Health 2003; 117: 43-48.
5. Weild AR, et al. Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: A national survey. Communicable Disease and Public Health 2000; 3: 121-126.
6. Grupo Noroeste para el estudio de la Hepatitis C en el medio penitenciario. Seroprevalence of hepatitis C virus infection at the time of entry to prison in the prison population in the north-east of Spain. Revista Española de Salud Pública 1998; 72: 43-51.
7. Long J, et al. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in entrants to Irish prisons: A national cross sectional survey. British Medical Journal 2001; 323: 1209-1213.
8. Backmund M, et al. Hepatitis C virus infection in injection drug users in Bavaria: Risk factors for sero-positivity. European Journal of Epidemiology 2003; 18: 563-568.
9. Gore SM, et al. Prevalence of hepatitis C in prisons: WASH-C surveillance linked to self-reported risk behaviours. QJM 1999; 92: 25-32.
10. Macalino GE, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. American Journal of public Health 2004; 94: 1218-1223.
11. Solomon L, et al. Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities. Journal of Urban Health 2004; 81: 25-37.
12. Christensen PB, et al. Prevalence and incidence of bloodborne viral infections among Danish prisoners. European Journal of Epidemiology 2000; 16: 1043-1049.
13. Ogilvie EL, et al. Hepatitis infection among adolescents resident in Melbourne Juvenile Justice Centre: Risk factors and challenges. Journal of Adolescent Health 1999; 25: 46-51.
14. Maher L, et al. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in southwestern Sydney, Australia. Journal of Gastroenterology and Hepatology 2004; 19: 1114-1120.
15. Rhodes T, Davis M, Judd A. Hepatitis C and its risk management among drug injectors in London: Renewing harm reduction in the context of uncertainty. Addiction 2004; 99: 621-633.
16. Stark.K, et al. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. International Journal of Epidemiology 1997; 26: 1359-1366.
17. Murray KF, et al. Prevalence of hepatitis C virus infection and risk factors in an incarcerated juvenile population: A pilot study. Pediatrics 2003; 111: 153-157.
18. Baillargeon J, et al. Hepatitis C seroprevalence among newly incarcerated inmates in the Texas correctional system. Public Health 2003; 117: 43-48.
19. Bundesministerium des Inneren. Jahresstatistik 2003 (www.bmi.bund.de/ cln_012/nn_165290/Internet/Content/Themen/Vertriebene_Spaetaussiedler/ statistiken/jahresstatistik_2005.html).
20. Wai CT, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
21. Lehmann M, et al. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. Journal of Medical Virology 2004; 73: 387-391.
22. Post JJ, et al. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. Journal of Infectious Diseases 2004; 189: 1846-1855.
23. Wiese M, et al. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: A 20-year multicenter study. Hepatology 2000; 32: 91-96.
24. Vogt M, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. New England Journal of Medicine 1999; 341: 866-870.
25. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36: 21-29.
26. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: 237-244.
27. Pessione F, et al. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology 2001; 34: 121-125.
28. Hezode C, et al. Impact of smoking on histological liver lesions in chronic hepatitis C. Gut 2003; 52: 126-129.